Vandria secures $30.7 Million in Series A funding

Vandria secures $30.7 Million in Series A funding to advance groundbreaking mitophagy therapies.

The Vaud-based company announced the second closing of its Series A financing, bringing the final amount raised to date to $30.7 Million (CHF 28.3 Million). Vandria welcomes new institutional investors Hevolution Foundation and Dolby Family Ventures, who have joined its founding venture investor, ND Capital.

Vandria is developing first-in-class small molecule mitophagy inducers against a novel target to rejuvenate cells and treat age-related and chronic diseases.

Since the first Series A close in December at $20.6 Million (CHF 18 Million), backed by ND Capital and a small syndicate of private investors, Vandria has made rapid progress. It has further developed its platform and portfolio, and advanced its lead program, VNA-318, a patent-protected, brain-penetrant, first-in-class mitophagy inducer. VNA-318 is on track to enter clinical trials in Europe in the coming weeks. The company has also expanded its team and moved to dedicated lab facilities at Superlab Suisse on the Biopôle Lausanne campus.

In addition to the equity financing, Vandria has secured CHF4.2 Million in prestigious non-dilutive funding: two Innosuisse grants to support VNA-318 and an Eurostars grant to support the generation of pre-clinical data for mitophagy drug candidates in Vandria’s muscle program.

Klaus Dugi, CEO of Vandria, said: “I am delighted to welcome Hevolution Foundation and Dolby Family Ventures, alongside ND Capital, to support our transformation into a clinical stage company. This Financing will enable us to progress further in clinical development with runway from the series A to complete the Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) first-in-man Phase 1 study of VNA-318 and to initiate three parallel Phase 1b / 2a efficacy studies in 2025, subject to positive progress in the Phase 1 and regulatory approvals.”

Source: press release